Can-Fite’s Phase 2a Pancreatic Cancer Data Shows 35% of Patients Remain on Namodenoson Therapy, One for Over 16 Months
Durable Disease Stabilization Emerges in Advanced Pancreatic Cancer Trial
Can-Fite BioPharma (NYSE:CANF) released promising interim results from its Phase 2a trial evaluating namodenoson for advanced pancreatic cancer. As of the current update, 35% of enrolled patients remain on therapy—including one patient continuing treatment for more than 16 months. This stands out in a patient population known for its limited treatment options and rapid disease progression.
Key Findings Highlight Prolonged Benefit and Safety
The fully enrolled open-label study included 20 evaluable patients whose cancers had worsened after first-line treatment or who could not tolerate standard therapies. Key findings from the interim analysis include:
| Trial Detail | Result |
|---|---|
| Patients Enrolled | 20 |
| % Remaining on Namodenoson | 35% |
| Longest Treatment Duration | 16+ months |
| % with Stable Disease | >30% |
| Primary Endpoint | Met (Favorable Safety Profile) |
Stable disease—meaning the cancer did not worsen—was observed in over 30% of evaluable patients. All participants received namodenoson 25 mg orally twice daily in ongoing 28-day cycles, with regular safety monitoring. The drug’s safety profile was consistent with previous studies, and no new concerns were identified.
Clinical Context: Durable Responses in a Difficult Setting
Pancreatic cancer remains one of the most challenging malignancies to treat, with few effective second-line therapies. The prolonged treatment durations and stable disease rates seen in this study suggest namodenoson may offer durable clinical benefit for some patients where options are limited. The fact that one patient has remained on therapy for over 16 months is notable given typically short progression timelines in this cancer.
What’s Next: Full Efficacy Results and Broader Pipeline Momentum
While detailed progression-free and overall survival results will be forthcoming, these early signals support continued investigation. Namodenoson, a selective A3 adenosine receptor agonist, has Orphan Drug Designation from the U.S. FDA for pancreatic cancer and is also in clinical development for advanced liver cancer and metabolic disease.
Can-Fite plans to release top-line efficacy data—including objective response rates and survival outcomes—in the coming months at a major clinical conference, providing greater insight into the therapy’s potential impact.
Takeaway: Early Stability and Safety Signal Potential for Namodenoson
With 35% of patients with advanced pancreatic cancer remaining on therapy and durability extending beyond a year for at least one individual, namodenoson’s latest Phase 2a data present a positive signal in a population with few alternatives. Investors and clinicians will be closely watching for the full efficacy dataset as Can-Fite advances its broader pipeline.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI